American Century Companies Inc. Cuts Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

American Century Companies Inc. lessened its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 18.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 85,466 shares of the specialty pharmaceutical company's stock after selling 19,447 shares during the period. American Century Companies Inc. owned about 0.27% of Collegium Pharmaceutical worth $2,449,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in COLL. FMR LLC lifted its holdings in Collegium Pharmaceutical by 1,532.2% during the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company's stock worth $1,459,000 after buying an additional 35,439 shares in the last quarter. Verition Fund Management LLC raised its stake in shares of Collegium Pharmaceutical by 35.1% in the third quarter. Verition Fund Management LLC now owns 14,042 shares of the specialty pharmaceutical company's stock valued at $543,000 after acquiring an additional 3,652 shares in the last quarter. Janus Henderson Group PLC grew its stake in Collegium Pharmaceutical by 399.4% during the 3rd quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company's stock worth $2,686,000 after purchasing an additional 55,572 shares in the last quarter. Wellington Management Group LLP increased its holdings in Collegium Pharmaceutical by 17.2% during the 3rd quarter. Wellington Management Group LLP now owns 114,640 shares of the specialty pharmaceutical company's stock worth $4,430,000 after purchasing an additional 16,784 shares during the period. Finally, Barclays PLC raised its position in Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after purchasing an additional 45,291 shares in the last quarter.

Remove Ads

Collegium Pharmaceutical Stock Up 6.6 %

NASDAQ:COLL traded up $1.63 during midday trading on Friday, hitting $26.30. 617,106 shares of the company were exchanged, compared to its average volume of 443,076. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The company has a market capitalization of $845.07 million, a PE ratio of 11.34 and a beta of 0.76. The company has a fifty day simple moving average of $29.14 and a 200 day simple moving average of $31.60.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the transaction, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the transaction, the chief financial officer now owns 177,195 shares in the company, valued at approximately $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 81,693 shares of company stock valued at $2,334,994. Insiders own 3.98% of the company's stock.

Analysts Set New Price Targets

COLL has been the topic of several analyst reports. StockNews.com raised shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Friday. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Needham & Company LLC reissued a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday. Finally, Piper Sandler decreased their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical has a consensus rating of "Buy" and an average target price of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.